|

Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer

RECRUITINGSponsored by The First Hospital of Jilin University
Actively Recruiting
SponsorThe First Hospital of Jilin University
Started2024-07-15
Est. completion2025-12-31
Eligibility
Age35 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06714903

Summary

The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.

Eligibility

Age: 35 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Clinical and pathological diagnosis of metastatic colorectal cancer
* 35-75 years old (both ends inclusive)
* complete clinical information
* signed informed consent

Exclusion Criteria:

* combined with severe respiratory and circulatory diseases
* combined with other malignant tumors
* recent severe active bleeding, uncontrolled active infection or active peptic ulcer
* moderate to severe renal insufficiency
* other circumstances that are judged by the investigator to be unsuitable for participating in this study

Conditions2

CancerColorectal Neoplasms Malignant

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.